Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Curran MA, Allison JP.

Cancer Res. 2009 Oct 1;69(19):7747-55. doi: 10.1158/0008-5472.CAN-08-3289. Epub 2009 Sep 8.


PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Curran MA, Montalvo W, Yagita H, Allison JP.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. doi: 10.1073/pnas.0915174107. Epub 2010 Feb 16.


CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Quezada SA, Peggs KS, Curran MA, Allison JP.

J Clin Invest. 2006 Jul;116(7):1935-45. Epub 2006 Jun 15.


Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.

J Exp Med. 2001 Aug 20;194(4):481-9.


Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.


Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.

Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP.

PLoS One. 2011 Apr 29;6(4):e19499. doi: 10.1371/journal.pone.0019499.


Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G.

Cancer Res. 2000 Jun 15;60(12):3239-46.


Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.

Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M.

Cancer Immunol Immunother. 2013 Apr;62(4):629-37. doi: 10.1007/s00262-012-1371-9. Epub 2012 Nov 10.


Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.


TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.

Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K.

Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10.


Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.

Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Soo Hoo W, Carlo DJ.

Gene Ther. 2002 Oct;9(19):1302-11.


Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD.

Cancer Res. 2004 Aug 1;64(15):5407-14.


CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.

Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD.

J Immunol. 2003 Mar 15;170(6):3401-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk